Key Takeaways
- Lupin will invest USD 250 million over five years in a new Coral Springs, Florida, manufacturing facility.
- The site will produce over 25 essential respiratory drugs and generate more than 200 skilled jobs by 2030.
- The project strengthens domestic supply chains and supports affordable access to vital medicines.
- Florida’s growing life sciences sector will benefit from advanced pharmaceutical infrastructure and workforce development.
Lupin Expands U.S. Manufacturing Footprint with New Coral Springs Site
Global pharmaceutical company Lupin has announced plans to build a state-of-the-art manufacturing facility in Coral Springs, Florida, investing around USD 250 million over the next five years. The project encompasses research and development, infrastructure, and capital expansion, aiming to enhance the U.S. supply of critical respiratory treatments.
The company expects the site to become operational by the end of the decade, adding over 200 skilled positions in Broward County. The move highlights Lupin’s continued commitment to bolstering medicine security and local production capacity in the United States.
Strengthening Drug Supply and Workforce in Florida
The 70,000-square-foot facility will sit on more than five acres of newly acquired land and focus on manufacturing over 25 key respiratory medicines, including albuterol inhalers widely used in asthma care. The new plant is designed to support both civilian and defense medical needs, ensuring a steady supply of affordable therapies amid global supply chain disruptions.
“This expansion reinforces Lupin’s long-term commitment to U.S. patients and our presence in Florida,” said Christoph Funke, Chief Technical Operations Officer. “Our new facility will advance innovation, quality, and reliability, while helping safeguard America’s pharmaceutical resilience.”
State Officials Welcome Major Investment in Life Sciences
Florida Secretary of Commerce J. Alex Kelly welcomed Lupin’s decision, emphasizing the state’s growing prominence in the pharmaceutical sector.
“Lupin’s investment underscores Florida’s emergence as a national leader in pharmaceutical and medical device manufacturing,” Kelly said. “Our focus on R&D, education, and workforce training has positioned Florida as a magnet for high-impact investments like this one.”
The state currently ranks second nationwide in pharmaceutical and medical device manufacturing, supported by strong university partnerships and a thriving innovation ecosystem.
Part of a Broader Global Manufacturing Push
Lupin’s Coral Springs project follows a global expansion strategy across multiple continents. The company recently announced significant investments in India, with over USD 1 billion dedicated to enhancing production and technical capacity through contract manufacturing networks.
This move aligns with broader industry trends as major pharmaceutical players, such as Eli Lilly, which is investing over USD 11 Billion across several new U.S. plants, seek to localize production amid regulatory and trade pressures.
Lupin’s latest initiative reinforces its position as a leader in complex generics and respiratory medicine, while contributing to U.S. healthcare resilience and local job creation.
